Form 8-K Summary
Registrant and reporting period: The filing is by MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc. The report covers an event occurring February 19, 2022 and was signed February 23, 2022. MedTech is a special purpose acquisition company pursuing a proposed business combination with Memic Innovative Surgery, Ltd.
Material Corporate Changes
- Maurice R. Ferré, M.D. resigned effective immediately from MedTech’s Board of Directors and all other positions with the company.
- The filing states that Dr. Ferré’s resignation was not related to any disagreement with MedTech. He will remain Chairman of Memic Innovative Surgery, Ltd.
- Manuel Aguero was appointed to MedTech’s Audit Committee and Compensation Committee. The Board determined that he is independent under applicable Nasdaq and SEC requirements.
- Following the appointment, the Audit Committee consists of Ivan Delevic as chair, Karim Karti, and Manuel Aguero. The Compensation Committee consists of Manuel Aguero as chair and Martin Roche, M.D.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics. It is focused on a director resignation, committee appointments, and the proposed business combination.
Business Combination, Outlook, and Risks
MedTech and Memic have filed transaction-related materials with the SEC, including an effective Form F-4 registration statement and a definitive proxy statement filed February 14, 2022. Stockholders and investors were urged to review those documents before making voting or investment decisions.
The filing identifies risks relating to the proposed transaction, including failure to obtain stockholder approval, failure to satisfy closing conditions, termination of the business combination agreement, redemption requests by public stockholders, disruption to Memic’s operations, manufacturing and commercialization challenges, adoption of the Hominis Surgical System, retention of key employees, competition, regulatory and legislative changes, COVID-19 and other health or natural disasters, cybersecurity and privacy, litigation, Nasdaq listing, market volatility, operations in Israel, and unexpected costs.
The filing contains forward-looking statements regarding the expected timing, completion, and effects of the proposed business combination. It states that actual results may differ materially and that the listed risk factors are not exhaustive.
Key Facts to Verify
- Confirm that the intended filing subject is MedTech Acquisition Corporation rather than Trisalus Life Sciences, Inc.
- Review the Form F-4 and definitive proxy statement for transaction terms, approval requirements, redemption provisions, and expected closing conditions.
- Verify the post-resignation composition and independence of MedTech’s Board committees.
- Assess Memic’s product commercialization, regulatory, manufacturing, financing, and Nasdaq-listing risks.
- Review subsequent SEC filings for any changes to the proposed business combination, committee structure, or transaction status.